Groundbreaking HIV Prevention: First Twice-Yearly Shot Shows 100% Effectiveness in Study

MEXICO CITY (AP) — A new twice-yearly shot aimed at preventing the AIDS virus has shown promising results. In studies, this shot was 100% effective in preventing HIV infections in women and nearly as effective in men. Drugmaker Gilead plans to sell affordable, generic versions of this drug in 120 poorer countries, mainly in Africa, Southeast Asia, and the Caribbean. However, most of Latin America is excluded, raising concerns about missed opportunities to combat the disease.

Winnie Byanyima, executive director of UNAIDS, praised the innovation but emphasized the need for access in at-risk regions. Last year, an estimated 630,000 AIDS deaths were reported, the lowest since 2004, indicating a pivotal moment in the fight against the epidemic.

The drug, named lenacapavir and marketed as Sunlenca, is already available for treating HIV in several regions. Gilead plans to seek approval for its use in HIV prevention. Experts highlight that this new prevention method could significantly aid marginalized groups, such as gay men, sex workers, and young women. Participants in recent studies shared their experiences, noting the fear of discrimination that kept them from seeking existing prevention methods.

Health officials in Mexico have not confirmed how widely available these shots will be under the national health care system. There are hopes for future availability, especially as generics become accessible. Gilead has stated a commitment to improving HIV prevention access in high-need areas, while advocacy groups in Latin America have pressed for broader access to this new prevention tool amid rising infection rates.

Dr. Chris Beyrer from Duke University noted that the availability of Sunlenca could significantly aid those in heavily affected regions. At the same time, rising HIV rates in vulnerable populations in Latin America must be tackled urgently.

While the focus remains on the effectiveness of Sunlenca in preventing HIV, the challenge ahead lies in ensuring it reaches everyone in need.